Jazz Pharmaceuticals to acquire Chimerix for $935m.

Jazz Pharmaceuticals, a global biopharmaceutical company with a focus on oncology and neuroscience, agreed to acquire Chimerix, a biopharmaceutical company, for $935m. "Adding dordaviprone to our oncology R&D pipeline will further diversify our portfolio with a medicine that addresses a significant unmet need with no other FDA-approved therapies and limited treatment options for this patient population. If approved, dordaviprone has the potential to rapidly become a standard of care for a rare oncology disease and also contribute durable revenue beginning in the near-term," Bruce Cozadd, Jazz Pharmaceuticals Chairman and CEO.